A detailed history of Macquarie Group LTD transactions in Amgen Inc stock. As of the latest transaction made, Macquarie Group LTD holds 399,505 shares of AMGN stock, worth $105 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
399,505
Previous 237,288 68.36%
Holding current value
$105 Million
Previous $74.1 Million 73.62%
% of portfolio
0.14%
Previous 0.09%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$309.38 - $337.38 $50.2 Million - $54.7 Million
162,217 Added 68.36%
399,505 $129 Million
Q2 2024

Aug 09, 2024

SELL
$262.75 - $319.31 $10.5 Million - $12.8 Million
-40,088 Reduced 14.45%
237,288 $74.1 Million
Q1 2024

May 14, 2024

SELL
$268.87 - $324.56 $6.68 Million - $8.07 Million
-24,853 Reduced 8.22%
277,376 $78.9 Million
Q4 2023

Feb 14, 2024

BUY
$255.7 - $288.46 $5.24 Million - $5.92 Million
20,510 Added 7.28%
302,229 $87 Million
Q3 2023

Nov 14, 2023

BUY
$218.65 - $271.46 $10.7 Million - $13.3 Million
49,052 Added 21.08%
281,719 $75.7 Million
Q2 2023

Aug 14, 2023

SELL
$214.27 - $253.37 $12.6 Million - $14.9 Million
-58,713 Reduced 20.15%
232,667 $51.7 Million
Q1 2023

May 15, 2023

BUY
$225.79 - $275.2 $2.35 Million - $2.87 Million
10,418 Added 3.71%
291,380 $70.4 Million
Q4 2022

Feb 21, 2023

SELL
$229.03 - $291.01 $2.45 Million - $3.11 Million
-10,703 Reduced 3.67%
280,962 $73.8 Million
Q3 2022

Nov 14, 2022

BUY
$224.46 - $253.15 $261,944 - $295,426
1,167 Added 0.4%
291,665 $65.7 Million
Q2 2022

Aug 15, 2022

BUY
$230.71 - $256.74 $1.1 Million - $1.23 Million
4,772 Added 1.67%
290,498 $70.7 Million
Q1 2022

May 16, 2022

SELL
$219.27 - $242.57 $2.3 Million - $2.54 Million
-10,479 Reduced 3.54%
285,726 $69.1 Million
Q4 2021

Feb 11, 2022

SELL
$198.88 - $227.6 $17 Million - $19.4 Million
-85,256 Reduced 22.35%
296,205 $66.6 Million
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $41.6 Million - $48.7 Million
-195,905 Reduced 33.93%
381,461 $81.1 Million
Q2 2021

Aug 13, 2021

BUY
$233.58 - $259.14 $47.6 Million - $52.8 Million
203,708 Added 54.52%
577,366 $141 Million
Q1 2021

May 14, 2021

SELL
$221.91 - $258.6 $1.56 Million - $1.81 Million
-7,014 Reduced 1.84%
373,658 $93 Million
Q4 2020

Feb 16, 2021

BUY
$216.38 - $257.67 $102,131 - $121,620
472 Added 0.12%
380,672 $87.5 Million
Q3 2020

Nov 13, 2020

BUY
$234.65 - $260.95 $689,167 - $766,410
2,937 Added 0.78%
380,200 $96.6 Million
Q2 2020

Aug 11, 2020

BUY
$197.81 - $242.74 $5.19 Million - $6.37 Million
26,246 Added 7.48%
377,263 $89 Million
Q1 2020

May 15, 2020

BUY
$182.24 - $241.7 $10.7 Million - $14.2 Million
58,950 Added 20.18%
351,017 $71.2 Million
Q4 2019

Feb 14, 2020

BUY
$189.21 - $243.2 $2.99 Million - $3.84 Million
15,808 Added 5.72%
292,067 $70.4 Million
Q3 2019

Nov 14, 2019

BUY
$174.11 - $208.62 $5.91 Million - $7.08 Million
33,943 Added 14.01%
276,259 $53.5 Million
Q2 2019

Aug 14, 2019

BUY
$166.7 - $195.41 $6.56 Million - $7.69 Million
39,377 Added 19.4%
242,316 $44.7 Million
Q1 2019

May 15, 2019

SELL
$180.87 - $203.88 $1.01 Million - $1.14 Million
-5,609 Reduced 2.69%
202,939 $38.6 Million
Q4 2018

Feb 15, 2019

BUY
$178.4 - $208.25 $7.13 Million - $8.32 Million
39,941 Added 23.69%
208,548 $40.6 Million
Q3 2018

Nov 15, 2018

BUY
$185.29 - $208.89 $1.9 Million - $2.14 Million
10,237 Added 6.46%
168,607 $35 Million
Q2 2018

Aug 14, 2018

BUY
$166.05 - $186.51 $132,840 - $149,208
800 Added 0.51%
158,370 $29.2 Million
Q1 2018

May 11, 2018

SELL
$169.43 - $198.0 $6.73 Million - $7.87 Million
-39,748 Reduced 20.14%
157,570 $26.9 Million
Q4 2017

Feb 15, 2018

SELL
$168.79 - $188.59 $3.44 Million - $3.85 Million
-20,400 Reduced 9.37%
197,318 $34.7 Million
Q3 2017

Nov 08, 2017

BUY
$167.29 - $191.0 $36.4 Million - $41.6 Million
217,718
217,718 $40.6 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.